PET Imaging agents for a4b2 Nicotinic Receptors
PET Imaging agents for a4b2 Nicotinic Receptors
批准号:
10060568
负责人:
Bradley T Christian
金额:
$24.91万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-01 至 2024-07-31
关键词:
AffinityAgeAgingAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAnteriorApplications GrantsAreaAutopsyAutoradiographyBindingBladderBrainBrain DiseasesBrain regionCaliforniaCognitionCorpus CallosumDevelopmentDiagnosisDiseaseDisease modelEvaluationFemaleFluorescent ProbesFunctional disorderFundingGenderGoalsGroupingHippocampus (Brain)HumanImageInjectionsInternal CapsuleKnock-outKnockout MiceLearningMalignant neoplasm of lungMeasuresMemoryMethodsMusNerve DegenerationNeurobiologyNeurodegenerative DisordersNicotine DependenceNicotinic ReceptorsOrganOutcomeParkinson DiseasePhysiologicalPlayPositron-Emission TomographyRadiometryRoleScanningSchizophreniaSliceTestingThalamic structureTobacco DependenceTranslationsUniversitiesWild Type MouseWisconsinage effectage groupage relatedbasecognitive enhancementcognitive functiondesignfrontal lobegender differencehuman imaginghuman studyhuman subjectimaging agentimaging modalitylung cancer screeningmalemouse modelprogramsputamenreceptorreceptor functionthalamocortical tracttherapeutic developmenttranslational studytreatment planningwhite matter
中文摘要
项目摘要
尼古丁受体与许多病理生理学有关。在加州大学-
欧文大学(UCI)和威斯康星大学麦迪逊分校(UWM),我们有几个主要的项目,将获得
尼古丁受体的成像。这些包括:1)衰老和神经退行性疾病计划; 2)
与尼古丁依赖有关的研究方案; 3)肺癌早期检测方案,以及4)
学习和记忆的神经生物学。在过去的三年中,我们成功地
完成了[18 F]Nifene的初始人体PET研究(重测和辐射剂量测定),
结果:1)[18F]Nifene需要40分钟动态扫描进行定量; 2)膀胱是关键
器官,每年可以进行4次5 mCi注射的PET研究; 3)Nifene测量104 × 102,103 × 102和104 × 102。
NIF 2受体亚型; 4)Nifene是部分激动剂; 5)[18 F]Nifene能够检测丘脑辐射(白色
物质束); 6)女性比男性显示出更大的[18F]Nifene结合;以及7)对[18F]Nifene没有衰老影响
观察到结合。由于最初的研究仅包括8名受试者,因此需要更大的受试者组,
为了证实使用[18F]Nifene的男女差异和衰老的发现。在这3年的更新中
我们的目标是:1)使用32名健康受试者(16名男性,16名女性)确认男女差异,
通过将16名20多岁的人(8名男性,8名女性)和16名70多岁的人(8名男性,8名女性)分组,在所有大脑区域中检查衰老的影响。
2)在第二个目标中,为了寻求[18F]Nifene PET的翻译以研究人类神经变性,我们
建议研究阿尔茨海默病(AD)和帕金森病(PD)的死后大脑。两个大脑
根据以前的研究结果选择了这些区域,前扣带回(带体
胼胝体)和海马(含有CA 1/下托)。这些将在3中使用[18F]Nifene进行评价
组:对照组、AD组和PD组(每组32例受试者,16例男性,16例女性)。3)第三个目标是评估
使用敲除(KO)小鼠的[18F]Nifene与受体亚型的结合。将研究K12和K14 KO
使用[18 F]Nifene PET和放射自显影术,将在野生型中评估男性-女性和衰老效应
(WT)小鼠这一更新申请将有助于确定女性的[18F]Nifene水平更高
结合(更大的α 4 β 2* 受体的可用性),对[18 F]Nifene结合没有衰老效应,
在某些脑区域的神经变性中,β 4 β 2* 受体发生变化。此外,小鼠
使用[18F]Nifene的研究将提供有关受体选择性和与人类相似性的信息,
性别效应和衰老的影响。这些研究对于在中国开展翻译研究具有重要意义和必要性。
神经退行性变,小鼠模型和人类。
英文摘要
Project Summary
Nicotinic 42* receptors have been implicated in a number of pathophysiologies. At University of California-
Irvine (UCI) and University of Wisconsin-Madison (UWM), we have several major programs that would gain
from imaging nicotinic receptors. These include: 1) Program in aging and neurodegenerative disorders; 2)
Program on studies related to nicotine dependence; 3) Program in the early detection of lung cancer, and 4)
Neurobiology of learning and memory. During the previous 3-year funding period we have successfully
completed initial human PET studies (test-retest and radiation dosimetry) with [18F]Nifene with the following
outcomes: 1) [18F]Nifene requires a 40 min dynamic scan for quantitation; 2) Urinary bladder is the critical
organ, and 4 PET studies with 5 mCi injections can be done annually; 3) Nifene measures 42, 32 and
22 receptor subtypes; 4) Nifene is a partial agonist; 5) [18F]Nifene is able to detect thalamic radiations (white
matter tracts); 6) Females show greater [18F]Nifene binding than males; and 7) No aging effect on [18F]Nifene
binding was observed. Since the initial study included only 8 subjects, a larger group of subjects is required in
order to confirm the findings of male-female differences and aging using [18F]Nifene. In this 3-year renewal
application our goals are: 1) Confirm male-female differences using 32 healthy subjects (16M, 16F) and
examine aging effects by grouping 16 (8M, 8F) in their 20’s and 16 (8M, 8F) in their 70’s in all brain regions.
2) In the second goal, in pursuit of translation of [18F]Nifene PET to study human neurodegeneration, we
propose to study postmortem brains of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Two brain
areas have been chosen based on previous findings of their significance, anterior cingulate (with corpus
callosum) and hippocampus (containing CA1/subiculum). These will be evaluated using [18F]Nifene in 3
groups: controls, AD and PD (32 subjects in each group, 16M, 16F). 3) The third goal is to evaluate degree of
binding of [18F]Nifene to the receptor subtypes using knock-out (KO) mice. Both 2 and 4 KO will be studied
using [18F]Nifene PET and autoradiography and a male-female and aging effect will be evaluated in wild-type
(WT) mice. This renewal application will help to ascertain that females have greater levels of [18F]Nifene
binding (greater availability of 42* receptors), there is no aging effect on [18F]Nifene binding and whether
there is a change in 42* receptors in neurodegeneration in certain brain regions. Additionally, the mice
studies using [18F]Nifene will provide information on receptor selectivity and similarities with humans in terms
of gender effects and aging. These studies will be important and necessary to carry translational studies in
neurodegeneration, both mice models and humans.
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model.
针对肺癌中的组蛋白脱乙酰酶进行早期诊断:(18)NNK 治疗的 A/J 小鼠模型的 F-FAHA PET/CT 成像。
DOI:
--
发表时间:
2014
期刊:
American journal of nuclear medicine and molecular imaging
影响因子:
2.5
作者:
[Tang,Wayland, Kuruvilla,SharonA, Galitovskiy,Valentin, Pan,Min-Liang, Grando,SergeiA, Mukherjee,Jogeshwar]
通讯作者:
Mukherjee,Jogeshwar
DOI:
10.3390/cells11244000
发表时间:
2022-12-10
期刊:
Cells
影响因子:
6
作者:
[]
通讯作者:
Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors.
(S)-[(18)F]fesetron 在大鼠大脑中的合成和评估,作为血清素 5-HT3 受体的潜在 PET 成像剂。
DOI:
10.1016/j.bmcl.2016.03.018
发表时间:
2016
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[Pithia,NeemaK, Liang,Christopher, Pan,Xiang-Zuo, Pan,Min-Liang, Mukherjee,Jogeshwar]
通讯作者:
Mukherjee,Jogeshwar
DOI:
10.1186/2191-219x-1-6
发表时间:
2011-06-01
期刊:
EJNMMI research
影响因子:
3.2
作者:
[Kant R, Constantinescu CC, Parekh P, Pandey SK, Pan ML, Easwaramoorthy B, Mukherjee J]
通讯作者:
Mukherjee J
Development of fluorescence imaging probes for nicotinic acetylcholine α4β2∗ receptors.
烟碱乙酰胆碱α4β2β受体荧光成像探针的开发。
DOI:
10.1016/j.bmcl.2017.12.036
发表时间:
2018
期刊:
Bioorganic & medicinal chemistry letters
影响因子:
2.7
作者:
[Samra,GurleenK, Intskirveli,Irakli, Govind,AnithaP, Liang,Christopher, Lazar,Ronit, Green,WilliamN, Metherate,Raju, Mukherjee,Jogeshwar]
通讯作者:
Mukherjee,Jogeshwar
共 12 条
Core D: Neuroimaging Core
-
批准号:10454255
-
项目类别:
-
资助金额:$432.65万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)
-
批准号:10037875
-
项目类别:
-
资助金额:$2098.04万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
ABC-DS MOMs’ Supplement (Modification of Maternal AD risk in DS)
-
批准号:10595165
-
项目类别:
-
资助金额:$78.87万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Core D: Neuroimaging Core
-
批准号:10667576
-
项目类别:
-
资助金额:$665.08万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - Supplement
-
批准号:10833788
-
项目类别:
-
资助金额:$43.88万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)
-
批准号:10667549
-
项目类别:
-
资助金额:$2177.65万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)
-
批准号:10264834
-
项目类别:
-
资助金额:$1935.51万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Core D: Neuroimaging Core
-
批准号:10037879
-
项目类别:
-
资助金额:$209.8万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)
-
批准号:10454250
-
项目类别:
-
资助金额:$1923.36万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - KUMC Field Site Supplement
-
批准号:10844809
-
项目类别:
-
资助金额:$77.49万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)-04 Supplement 5
-
批准号:10665185
-
项目类别:
-
资助金额:$76.53万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Core D: Neuroimaging Core
-
批准号:10264838
-
项目类别:
-
资助金额:$425.11万
-
财政年份:2020
-
负责人:Bradley T Christian
-
依托单位:
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease
-
批准号:9743344
-
项目类别:
-
资助金额:$6.99万
-
财政年份:2015
-
负责人:Bradley T Christian
-
依托单位:
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease
-
批准号:9146760
-
项目类别:
-
资助金额:$355.69万
-
财政年份:2015
-
负责人:Bradley T Christian
-
依托单位:
[F-18]Mefway PET to measure 5-HT1A receptors in gene x environment interactions
-
批准号:7835573
-
项目类别:
-
资助金额:$21.89万
-
财政年份:2009
-
负责人:Bradley T Christian
-
依托单位:
[F-18]Mefway PET to measure 5-HT1A receptors in gene x environment interactions
-
批准号:7639993
-
项目类别:
-
资助金额:$18.17万
-
财政年份:2009
-
负责人:Bradley T Christian
-
依托单位:
A novel PET radiotracer to study 5HT-1A receptors in fetal alcohol exposure
-
批准号:7510115
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2008
-
负责人:Bradley T Christian
-
依托单位:
A novel PET radiotracer to study 5HT-1A receptors in fetal alcohol exposure
-
批准号:7688167
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2008
-
负责人:Bradley T Christian
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: